Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Valerie O'Neill"'
Autor:
Kayleigh Slater, Rosa Bosch, Kaelin Francis Smith, Chowdhury Arif Jahangir, Sandra Garcia-Mulero, Arman Rahman, Fiona O’Connell, Josep M. Piulats, Valerie O’Neill, Noel Horgan, Sarah E. Coupland, Jacintha O’Sullivan, William M. Gallagher, Alberto Villanueva, Breandán N. Kennedy
Publikováno v:
Frontiers in Medicine, Vol 9 (2023)
Uveal melanoma (UM) is an intraocular cancer with propensity for liver metastases. The median overall survival (OS) for metastatic UM (MUM) is 1.07 years, with a reported range of 0.84–1.34. In primary UM, high cysteinyl leukotriene receptor 1 (Cys
Externí odkaz:
https://doaj.org/article/eac8866d1abb4c86aceb6f7196a8a3cd
Publikováno v:
Irish Journal of Medical Science (1971 -).
Aim We aim to evaluate the impact of the COVID-19 pandemic on ocular oncology in Ireland, comparing uveal melanoma trends in 2019 to 2020. Methods Patients included for analysis were those that presented to the ocular oncology service from January 20
Autor:
Noel Horgan, Olya Scannell, Moya Cunningham, Amira Salih, Valerie O'Neill, Caroline Baily, Mary Dunne
Publikováno v:
Ocul Oncol Pathol
Background: Uveal melanoma and its treatment can influence the physical and psychological well-being of patients in a way that differs from other cancers. Factors influencing quality of life (QOL) include visual impairment, changes in appearance, day
Autor:
Giuseppe Gullo, Susan Kennedy, Noel Horgan, Paul M. Walsh, Valerie O'Neill, Moya Cunningham, Sandra Deady, Caroline Baily, Mary Dunne
Publikováno v:
Ocular Oncology and Pathology. 5:195-204
Purpose: To report the clinical features and epidemiology of uveal melanoma in Ireland. Methods: This was an observational study of 253 patients with a new diagnosis of uveal melanoma between June 2010 and December 2015. Main outcome measures include
Autor:
Tadhg Reddan, John Crown, Susan Kennedy, Aileen O'Meara, Fergus Keane, Cha Len Lee, Valerie O'Neill, Giuseppe Gullo, Helen Craig, Noel Horgan, Deirdre Smith, Emer Lynch, Naomi Walsh
Publikováno v:
Journal of Clinical Oncology. 39:e21585-e21585
e21585 Background: The treatment of MUM remains highly unsatisfactory. Single agent ICI produce low response rates. Two recent phase II trials of combination Ipilimumab and Nivolumab yielded response rates of 12% and 18%. We report the long-term surv